Bocidelpar

Bocidelpar

Bocidelpar
Clinical data
Other namesASP-0367; ASP0367; MA-0211; MA0211; MTB-1; MTB1
Routes of
administration		Oral[1][2]
Drug classPeroxisome proliferator-activated receptor delta (PPARδ) agonist
ATC code
  • None
Identifiers
  • (3R)-3-methyl-6-[2-[[5-methyl-2-[4-(trifluoromethyl)phenyl]imidazol-1-yl]methyl]phenoxy]hexanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
Chemical and physical data
FormulaC25H27F3N2O3
Molar mass460.497 g·mol−1
3D model (JSmol)
  • CC1=CN=C(N1CC2=CC=CC=C2OCCC[C@@H](C)CC(=O)O)C3=CC=C(C=C3)C(F)(F)F
  • InChI=1S/C25H27F3N2O3/c1-17(14-23(31)32)6-5-13-33-22-8-4-3-7-20(22)16-30-18(2)15-29-24(30)19-9-11-21(12-10-19)25(26,27)28/h3-4,7-12,15,17H,5-6,13-14,16H2,1-2H3,(H,31,32)/t17-/m1/s1
  • Key:FMOPHFSPINWSOV-QGZVFWFLSA-N

Bocidelpar (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names ASP-0367, MA-0211, and MTB-1) is a peroxisome proliferator-activated receptor delta (PPARδ) agonist which is or was under development for the treatment of mitochondrial myopathies, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Duchenne muscular dystrophy, and metabolic disorders.[1][3][2][4][5] It is taken orally.[1][2]

The clinical pharmacodynamics and pharmacokinetics of bocidelpar have been studied.[4][5]

Bocidelpar was originated by Mitobridge and is under development by Astellas Pharma and Mitobridge.[1][3][2] As of February 2026, bocidelpar is in phase 2/3 clinical trials for mitochondrial myopathies and phase 2 trials for ME/CFS, whereas no recent development has been reported for Duchenne muscular dystrophy or metabolic disorders.[1] However, other sources state that bocidelpar has been discontinued.[3][2] The drug was also under development for the treatment of hypoxia, but development for this indication was discontinued.[1] A phase 2 trial for mitochondrial myopathies was terminated due to lack of effectiveness.[1]

See also

References

  1. ^ a b c d e f g "Bocidelpar". AdisInsight. 28 February 2026. Retrieved 17 March 2026.
  2. ^ a b c d e "Bocidelpar Drug Profile". Ozmosi. 1 January 1900. Retrieved 17 March 2026.
  3. ^ a b c "Delving into the Latest Updates on Bocidelpar with Synapse". Synapse. 27 February 2026. Retrieved 17 March 2026.
  4. ^ a b Ito M, Tauscher-Wisniewski S, Smulders RA, Wojtkowski T, Yamada A, Koibuchi A, et al. (January 2022). "Single- and multiple-dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator-activated receptor delta in healthy adults: Results from a phase 1 study". Muscle & Nerve. 65 (1): 110–120. doi:10.1002/mus.27436. PMC 9298414. PMID 34642949.
  5. ^ a b Iwai M, Heo N, Hashimoto K, Guro S, Moy S, Spence A, et al. (August 2025). "Pharmacokinetics of Bocidelpar, ASP0367, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies". Clinical and Translational Science. 18 (8) e70310. doi:10.1111/cts.70310. PMC 12315851. PMID 40748778.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.